Science Corp Prepares First Brain Implant Trials with Reversible Neuron-Grown Interface
Max Hodak's $1.5B neurotech firm enlists Yale surgeon for 2027 human trials of biohybrid system that avoids tissue damage while commercializing vision-restoration device
Science Corp is preparing first-in-human trials of a brain-computer interface that grows lab neurons on a pea-sized sensor containing 520 electrodes, positioned to begin testing in 2027 under Yale neurosurgeon Dr. Murat Günel.
The biohybrid approach, developed by Max Hodak after his 2021 departure from Neuralink, fundamentally rejects the penetrating-electrode architecture pioneered by his former company. Instead of inserting thousands of rigid threads into brain tissue, Science Corp’s device rests on the cortical surface while lab-grown neurons bridge the gap between electronics and biological tissue — a design intended to eliminate cumulative damage from chronic implantation, according to TechCrunch.
The company completed a $230 million Series C round in March 2026 at a $1.5 billion valuation, raising total capital to $490 million since 2021. That funding underwrites parallel commercialization tracks: near-term approval of the PRIMA retinal implant for vision restoration, and longer-term development of cortical interfaces for motor control and cognitive applications.
$230M
$1.5B
$490M
Biohybrid Architecture vs. Metal Electrodes
The distinction between Science Corp’s approach and Neuralink’s penetrating threads centers on reversibility and signal fidelity. Metal electrodes implanted into neural tissue trigger inflammatory responses that degrade recording quality over months to years. Science Corp’s waffle-like device — so named for its grid pattern of chambers housing living neurons — avoids this problem by keeping electronics external to brain tissue while using biological cells as the signal interface, per IEEE Spectrum.
Dr. Günel, chair of Yale Medical School’s Department of Neurosurgery, called the biological bridging strategy “genius” in his assessment of the technology. His involvement signals academic validation beyond the venture-backed hype cycle that has characterized brain-computer interface development since 2020.
“The idea of using natural connections through neurons and creating a biological interface between the electronics and the human brain is genius.”
— Dr. Murat Günel, Chair of Neurosurgery, Yale Medical School
The modular design also enables rapid iteration. Science Corp’s BCI Ecosystem partnership with Neurosoft Bioelectronics, announced in February 2026, allows research groups to run first-in-human trials for under $5 million by leveraging pre-validated hardware and software modules — compared to $75-100 million for full-stack platform development, according to BusinessWire.
PRIMA Vision Restoration Clears Clinical Milestones
While cortical interface trials remain 12-18 months away, Science Corp’s PRIMA retinal implant has already demonstrated commercial viability. In trials involving 38 patients with geographic atrophy from age-related macular degeneration, 84% reported ability to read letters, numbers, and words — representing a mean improvement of 25.5 letters on the standardized ETDRS vision chart. The results were published in the New England Journal of Medicine in October 2025, as reported by MassDevice.
Hodak described the outcome as unprecedented: “To my knowledge, this is the first time that restoration of the ability to fluently read has ever been definitively shown in blind patients.”
| Metric | Result |
|---|---|
| Patients Reporting Reading Ability | 84% (32/38) |
| Mean Vision Improvement | +25.5 Letters (ETDRS) |
| Target Indication | Geographic Atrophy (AMD) |
| Addressable US Market | 11M Patients |
The device already holds FDA breakthrough designation, a status that accelerates regulatory review and increases approval probability. Science Corp expects CE mark approval in Europe by mid-2026, opening the first commercial markets while US regulatory processes continue.
Market Positioning Against Neuralink
Science Corp’s dual-track strategy — immediate revenue from vision restoration, longer-term upside from cortical interfaces — contrasts sharply with Neuralink’s singular focus on motor control for quadriplegic patients. The addressable market for age-related macular degeneration dwarfs the paralysis indication: 11 million AMD patients in the US alone versus roughly 300,000 individuals living with spinal cord injuries.
The global brain-computer interface market reached $2.4 billion in 2025 and is projected to grow to $6.16 billion by 2032 at a 14.4% compound annual growth rate, according to Coherent Market Insights. Hardware segments — where Science Corp competes — account for the majority of near-term revenue, though software and AI-powered decoding layers represent faster-growing categories.
Science Corp’s modular ecosystem directly targets the software opportunity. By providing validated recording hardware and wireless telemetry, the company enables third-party developers to build decoding algorithms and applications without replicating foundational infrastructure — effectively creating a platform business model while competitors pursue vertically integrated approaches.
Regulatory Precedent for Reversible Implants
The biohybrid architecture’s reversibility carries regulatory significance beyond technical performance. Current FDA frameworks for neural implants assume permanent placement with attendant safety requirements around long-term biocompatibility and failure modes. A device designed for removal without tissue damage opens alternative approval pathways — potentially accelerating timelines for exploratory applications where risk-benefit calculations differ from permanent interventions.
Science Corp has not publicly disclosed whether it will pursue breakthrough designation for the cortical interface. PRIMA’s designation suggests the company has established relationships with FDA reviewers and understands the agency’s priorities for neural devices — institutional knowledge that reduces regulatory uncertainty as trials advance.
What to Watch
PRIMA CE mark approval timing in H2 2026 will indicate whether Science Corp can execute commercial launches while advancing early-stage R&D — a dual capability that distinguishes durable platform companies from single-product ventures. European reimbursement negotiations following regulatory approval will reveal pricing power and real-world demand beyond clinical trial enthusiasm.
The 2027 cortical interface trial launch depends on finalizing surgical protocols with Dr. Günel and securing institutional review board clearances at Yale. Any delays push first-in-human data to 2028 or later, compressing the timeline advantage over Neuralink, which began human trials in early 2024.
Broader ecosystem adoption metrics — number of research groups licensing the BCI platform, publications using Science Corp hardware, third-party algorithm development — will signal whether the modular strategy gains traction or fragments into incompatible proprietary systems. The $5 million trial cost reduction only matters if academic and commercial partners actually deploy the platform at scale.